ELI LILLY Aktie

 

In einem Markt, der jede Schwäche sofort abstraft, hat Wolfe Research sieben Wachstumswerte gefunden, die genau das Gegenteil schaffen....

There is no end in sight for the company's incredible momentum....

Financing led by BVF Partners, L.P. and includes participation from Deep Track Capital and Perceptive Advisors alongside existing investors RA Capital Management, Insight Partners, NVIDIA, Catalio Capital Management, Eli Lilly and Company, Cooley, and Gaingels Proceeds will support......

The drug giant added to its immunotherapy portfolio....

Bloomberg's Michelle Davis joins Dani Burger on "Bloomberg Deals." Eli Lilly plans to buy Merida Biosciences Inc. for as much as $2.88 billion in cash to expand in autoimmune and allergic diseases, part of an effort to build beyond the weight-loss and diabetes markets that made it the largest pharmaceutical company in the world. (Source: Bloomberg)...

Eli Lilly just delivered one of the biggest quarters in Big Pharma history, yet the stock sits well below its 52-week high. A closer look at the pipeline and valuation reveals why the real opportunity may still be ahead....

Eli Lilly's 10th deal of 2026 expands its immunology pipeline, underscoring an aggressive push to build growth drivers beyond its blockbuster cardiometabolic franchise....

Nach dem starken Lauf der vergangenen Monate ist bei Eli Lilly zuletzt wieder etwas Abgabedruck aufgekommen. Vom Hoch bei knapp 1.290 US$ ging es auf aktuell rund 1.160 US$ zurück. Damit nähert sich die Aktie zwei Bereichen, die für einen neuen Einstieg beziehungsweise eine Gegenbewegung interessant werden könnten. Fundamental läuft es weiterhin stark Operativ gibt […] The post Eli Lilly-Aktie vor der Wende – wird der Rücksetzer zur Chance? first appeared on sharedeals.de....

The high-flying healthcare leader looks unstoppable right now....

LLY's $2.9B Merida deal adds immunology assets and expands its pipeline beyond obesity and diabetes into new growth areas....

Employer coverage of GLP-1 drugs is collapsing heading into 2027, but the FDA just gave Eli Lilly a specific piece of ammunition that could change the conversation in payer meetings for at least one slice of that market....

Restaurants Face GLP-1 Squeeze As Adopt-Or-Die Inflection Arrives Bernstein's latest GLP-1 tracker has Eli Lilly's Mounjaro leading script growth, with downstream effects compounding pressure on the restaurant industry already facing weakening consumer confidence, as gas prices nationwide remain above a politically sensitive $4 a gallon in late summer. Turning to UBS's latest note on the restaurant industry, Dennis Geiger, who covers U.S. restaurants and consumer discretionary names, wrote in a note on Sunday that restaurant investors are struggling to identify opportunities across the space amid sharp share-price volatility, weakening consumer confidence, growing uncertainty over the second-half outlook, and increasing GLP-1 adoption.  He points to a widening divide across the industry: Fast casual: Cava and Chipotle remain preferred, while Wingstop is attracting interest after its selloff. Investors see the NFL season, easier comparisons, and new value promotions as potential catalys...

Jim Cramer is flagging an Amgen drug that Wall Street has largely ignored, and he thinks the cardiovascular opportunity behind it could rival the most valuable pharmaceutical market ever created....

Novo Nordisk bringt die Wegovy-Tablette am heutigen 1. September in Deutschland auf den Markt. Damit erreicht Europas erste zugelassene Abnehmpille einen der größten Pharmamärkte des Kontinents – noch bevor Eli Lilly sein Konkurrenzprodukt hier anbieten kann. Das adressierbare Potenzial ist gewaltig, wird vorerst jedoch durch einen entscheidenden Faktor begrenzt: Die meisten Patienten müssen vollständig selbst […] The post Novo-Nordisk-Aktie: 13 Millionen Deutsche – wie groß wird der Pillen-Umsatz? first appeared on sharedeals.de....

Bei der Krankenversicherung sollte es eine stärkere Rolle spielen, wie gesund jemand lebt, sagt Alexander Horn vom Pharmakonzern Eli Lilly. Abnehmspritzen auf Krankenschein könnten manchmal für das System sogar günstiger sein, so Harald Sourij von der heimischen Diabetes-Gesellschaft....

Vier große Pharma-Namen, vier sehr verschiedene Bewertungen, und für Anleger entscheidet am Ende nicht die beste Bilanz, sondern der richtige Preis....

Der US-amerikanische Pharma-Riese hat zum Start in die neue Handelswoche erneut zugeschlagen. Für einen Milliarden-Dollar-Betrag sichert sich Eli Lilly die Dienste von Merida Biosciences, einer nicht börsennotierten Biotech-Gesellschaft mit einem Fokus auf die Allergologie und Autoimmunerkrankungen....

Hardly for the first time recently, the company is making a pricey acquisition....

Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...

Eli Lilly & Co. plans to buy Merida Biosciences Inc. for as much as $2.88 billion in cash to expand in autoimmune and allergic diseases, part of an effort to build beyond the weight-loss and diabetes markets that made it the largest pharmaceutical company in the world. Lilly has been on a record spending spree, having announced more than $20 billion in deals so far in 2026. The drugmaker has been using the windfall from its Zepbound and Mounjaro shots to diversify its pipeline, mainly targeting medicines in earlier stages as it seeks to position itself to develop the next blockbuster medicine. For more, we speak with Michelle Cortez, Bloomberg News Senior Editor for Global Business. (Source: Bloomberg)...